UC Davis Health Clinical Studies

A Study of the Experimental Medicine Erdafitinib for Advanced Urothelial Cancer (urinary tract cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the positive and negative effects of an investigational drug called erdafitinib. They will be compared to the effects of docetaxel (chemotherapy) and pembrolizumab (immunotherapy). Docetaxel and pembrolizumab are treatments already used to treat bladder cancer. Erdafitinib is a drug that targets a group of proteins called fibroblast growth factor receptors or FGFRs. Erdafitinib targets certain genetic changes affecting this group of proteins. Patients with these genetic changes have benefited from treatment with erdafitinib. Erdafitinib is not approved for use by the FDA. It is considered experimental in this study. Docetaxel is sold as Taxotere®. It received initial approval in the US in 1996. It is currently available for treatment of various cancers such as breast, prostate, lung, head and neck and bladder cancer. Pembrolizumab is sold as Keytruda®. It is approved both in Europe and in the USA by the FDA. It is used in patients with advanced urothelial cancer whose disease has worsened after initial treatment.

Drug study, Phase 3
Any, age 18 years or older

A Study of the Experimental Antibody PF-04518600 With or Without Axitinib for Metastatic Kidney Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in this research study because you have advanced kidney cancer. Your cancer was previously treated with immunotherapy and had progressed. You may now be a candidate for VEGF (Vascular endothelial growth factor) targeting agents in the third line of therapy. In cancer, VEGF is responsible for the formation and growth of new blood vessels in a tumor. This allows the tumor to grow much faster and to a much larger size than normal. So, drugs that target VEGF to suppress its effects will help slow tumor growth. Axitinib is one such drug and is a reasonable choice for you, provided you have not been treated with it in the past 12 months. PF-04518600 is a new experimental drug. An experimental drug is a drug that is currently not approved by the Food and Drug Administration (FDA) for sale in this country. PF-04518600 is an antibody (a type of protein) that has been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor cells to die. This study hopes to learn whether adding PF-04518600 to axitinib improves outcomes for people with advanced kidney cancer.

Biological study, Phase 2
Any, age 18 years or older

A Study of the Experimental Medicine Ropivacaine for Pain Control After Kidney Transplant

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is for patients scheduled to have kidney transplant surgery at the UC Davis Medical Center. It will compare two different methods for controlling pain after kidney transplant surgery. These methods are called TAP blocks and are designed to numb the nerves around the area of surgery. One method uses small implanted catheters to slowly give the anesthetic drug ropivacaine for two to three days after surgery. The other method uses a single injection of a long-acting anesthetic called liposomal bupivacaine. It lasts for two to three days after surgery. The study is designed to compare the effectiveness of these two different methods of decreasing pain. In addition, the study will compare the costs of these two different methods.

Drug study, Phase 4
Any, age 18 years or older

A Study of the Experimental Medicine Pazopanib for Locally Advanced or Metastatic Renal Cell Carcinoma (type of kidney cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the safety and effectiveness of experimental pazopanib plus abexinostat. It will be compared to the safety and effectiveness of pazopanib plus placebo. This will be accomplished by monitoring how your disease is progressing. The study doctor will: - see how the disease affects your ability to complete daily living activities - test your blood for levels of thyroid hormone and liver enzymes - review results from scans of your tumor(s) and electrocardiograms (ECG) (painless, noninvasive tests that show how your heart works). - monitor your general health and vital signs. There will also be a test to find out how much of the medication is in your blood.

Drug study, Phase 3
Any, age 18 years or older
Loading